Abstract: PO0758
Gaps in CKD Awareness Among People with Type 2 Diabetes
Session Information
- Diabetic Kidney Disease: Clinical
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Garza, Matthew, The diaTribe Foundation, San Francisco, California, United States
- Stevenson, Julia, dQ&A Market Research Inc., San Francisco, California, United States
- Suhl, Sara, dQ&A Market Research Inc., San Francisco, California, United States
- Sommi, Arvind S., The diaTribe Foundation, San Francisco, California, United States
- Close, Kelly L., The diaTribe Foundation, San Francisco, California, United States
- Wood, Richard S., dQ&A Market Research Inc., San Francisco, California, United States
Background
Diabetes is one of the most common causes of chronic kidney disease (CKD) in adults, with around 1 in 3 people with diabetes also living with CKD. Clinical guidelines recommend annual screenings of urinary albumin and glomerular filtration rate for people with type 2 diabetes (T2D). Previous studies have identified low awareness, testing and diagnosis of CKD among people with T2D and their healthcare providers (HCP). By drawing comparisons to cardiovascular disease (CVD), the present study aimed to assess awareness of CKD, renoprotective diabetes therapies, and kidney health metrics among people with T2D.
Methods
In February 2021, 1021 people with T2D from the dQ&A Patient Panel responded to an online survey assessing perceptions, knowledge, HCP engagement, and lifestyle behaviors related to CKD and CVD. Respondents received $10 USD for completing the survey. Data was collected with Qualtrics, prepared with IBM SPSS, and analyzed in MarketSight.
Results
Awareness of the link between T2D and CKD was lower than awareness of the link between T2D and CVD; 57% of respondents strongly agreed that having T2D increases the risk of CKD, compared to 63% who strongly agreed that T2D increases the risk of CVD. The percentage of respondents who often consider their personal risk of CKD (19%) was also lower than for CVD (26%).
Awareness of renoprotective and cardioprotective therapies was low overall. While 37% were aware that some T2D drugs are cardioprotective, only 22% were aware of renoprotective benefits. Respondents on SGLT-2 inhibitors or GLP-1 agonists were more likely to be highly aware of their cardioprotective benefits than their renoprotective benefits (52% vs. 30% for SGLT-2 users, 45% vs. 31% for GLP-1 users).
Knowledge of personal metrics for renal health indicators, eGFR (38%), and uACR (26%), lagged behind knowledge of diabetes and CVD metrics: weight (100%), A1C (98%), blood pressure (94%), and cholesterol (75%). Only 41% of respondents had discussed their CKD risk with a diabetes-related HCP, but those who had were more likely to be aware of CKD risks and therapies.
Conclusion
This data highlights a gap between T2D patients’ awareness of CKD risks and protective therapies and those of CVD. To prevent CKD and improve outcomes, this study emphasizes the need for better patient education on CKD’s connection to T2D.
Funding
- Commercial Support –